Nat Rev Dis Primers. 2019; 5: 9
Human herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during asymptomatic infection and Kaposi’s sarcoma.
PLoS Pathog. 2012; 8e1002486
Diagnosis and treatment of Kaposi’s sarcoma: European consensus interdisciplinary guide (EDF/EADO/EORTC).
Eur J Cancer. 2019; 114: 117-127
Treatments for classic Kaposi’s sarcoma: a systematic review of the literature.
J Am Acad Dermatol. 2013; 68: 313-331
Randomized trial comparing paclitaxel with pegylated liposomal doxorubicin for advanced Kaposi’s sarcoma associated with human immunodeficiency virus: evidence for palliation of symptoms with chemotherapy.
Cancer. 2010; 116: 3969-3977
Pomalidomide for symptomatic Kaposi’s sarcoma in HIV-infected and uninfected people: a phase I/II study.
J Clin Oncol. 2016; 34: 4125-4131
Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma.
Clin Cancer Res. 2021; 135244
PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma.
N Engl J Med. 2016; 374: 2542-2552
Tumor mutational load and response rate to PD-1 inhibition.
N Engl J Med. 2017; 377: 2500-2501
PD-1 mediates the functional depletion of activated NK cells in patients with Kaposi’s sarcoma.
Oncocible. 2016; 7: 72961-72977
PD-1 blockade with nivolumab in endemic Kaposi’s sarcoma.
Anne Oncol. 2018; 29: 1067-1069
Response to checkpoint inhibitor treatment in advanced classic Kaposi’s sarcoma: about a case and immunogenomic study.
J Natl Compr Canc Netw. 2018; 16: 797-800
Successful treatment of HIV-negative Kaposi’s sarcoma with ipilimumab and nivolumab and concurrent management of psoriasis and baseline bullous pemphigoid.
JAAD Case Rep. 2020; 6: 447-449
Case of metastatic Kaposi’s sarcoma successfully treated with anti-PD-1 immunotherapy.
J Oncol Pharm Pract. 2021; 27: 1766-1769
Safety evaluation of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study.
JAMA Oncol. 2019; 5: 1332-1339
1023MO AMC 095: A report on nivolumab (nivo) in advanced HIV-associated solid tumors (STs).
Anne Oncol. 2020; 31: S706
Letter to the editor: Could the immunogenicity of Kaposi’s sarcoma be linked more to viral antigens than to tumor mutational burden?.
J Natl Compr Canc Netw. 2018; 16: 1418-1419
Diagnosis and treatment of classic and iatrogenic Kaposi’s sarcoma: Italian recommendations.
Ital J Dermatol Venereol. 2021; 156: 356-365
Systemic therapeutic initiation in classic and endemic Kaposi’s sarcoma: risk factors and global multi-state modeling in a monocentric cohort study.
Cancers (Basel). 2021; 132519
Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-Saharan Africans.
JAMA. 2008; 299: 2770-2776
The evolutionary divergence of the HLA class I genotype has an impact on the efficacy of cancer immunotherapy.
NatMed. 2019; 25: 1715-1720
Advantage of the divergent allele at the level of human MHC genes: signatures of past and current selection.
Mol Biol Evol. 2018; 35: 2145-2158
Amino acid difference formula to help explain protein evolution.
Science. 1974; 185: 862-864
Successful treatment of HIV-associated Kaposi’s sarcoma with immune checkpoint blockade.
Cancer Immunol Res. 2018; 6: 1129-1135
Immune checkpoint inhibitors in transplantation – a case series and comprehensive review of current knowledge.
Transplantation. 2021; 105: 67-78
PD-1 blockade for disseminated Kaposi’s sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.
Immunotherapy. 2020; 12: 451-457
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of nonvisceral classic Kaposi’s sarcoma: a multicenter study.
J Invest Dermatol. 2008; 128: 1578-1580
Weekly paclitaxel for advanced classical aggressive Kaposi’s sarcoma: experience of 17 cases.
Br J Dermatol. 2008; 158: 1339-1344
Taxane treatment of refractory or life-threatening Kaposi’s sarcoma not associated with human immunodeficiency virus infection.
Cancer. 2006; 106: 1785-1789
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial.
Lancet. 2016; 387: 1540-1550
Risk factors for classic Kaposi’s sarcoma in a population-based case-control study in Sicily.
Cancer epidemiol biomarkers Prev. 2008; 17: 3435-3443
Safety, activity and immune correlates of anti-PD-1 antibodies in cancer.
N Engl J Med. 2012; 366: 2443-2454
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Med Oncol. 2016; 33: 93
Expression of PD-1 and PD-L1 in Kaposi’s sarcoma: a comparative study according to pathological stage and clinical characteristics.
J Cutan Pathol. 2021; 48: 221-228
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Clin Cancer Res. 2013; 19: 3462-3473
Expression of programmed cell death proteins in Kaposi’s sarcoma and cutaneous angiosarcoma.
J Immunother. 2020; 43: 169-174
PD-L1 expression in the tumor microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi’s sarcoma.
J Eur Acad Dermatol Venereol. 2019; 33: e269-e271
The advantage of HLA heterozygotes against HIV-1 is driven by quantitative and qualitative differences in the specific peptide presentation of HLA alleles.
Mol Biol Evol. 2020; 37: 639-650
Safety, activity and long-term results of pomalidomide in the treatment of Kaposi’s sarcoma in people with and without HIV infection.
Clin Cancer Res. 2022; (published online on January 19.)
Discontinuation of anti-PD-1 antibody treatment in the absence of disease progression or treatment-limiting toxicity: clinical outcomes in advanced melanoma.
Anne Oncol. 2019; 30: 1154-1161